Patents Examined by Michael C. Henry
  • Patent number: 11254792
    Abstract: A method for at least partial deacetylation of a biopolymer comprising acetyl groups, including: a1) providing a biopolymer including acetyl groups; a2) reacting the biopolymer including acetyl groups with hydroxylamine (NH2OH) or a salt thereof at a temperature of 100° C. or less for 2-200 hours to form an at least partially deacetylated biopolymer; and a3) recovering the at least partially deacetylated biopolymer.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: February 22, 2022
    Assignee: GALDERMA HOLDING SA
    Inventors: Johan Olsson, Craig Steven Harris
  • Patent number: 11248063
    Abstract: A glycosaminoglycan derivative which is obtainable by a process that includes the steps of N-desulfation of from 25% to 100% of the N-sulfated residues of a glycosaminoglycan, and oxidation, by periodate at a pH of from 5.5 to 10.0, of from 25% to 100% of the 2-N-, 3-O-non-sulfated glucosamine residues, and of the 2-O-non-sulfated uronic acid residues of said glycosaminoglycan, under conditions effective to convert adjacent diols and adjacent OH/NH2 to aldehydes. The process further includes reduction, by sodium borohydride, of said oxidized glycosaminoglycan, under conditions effective to convert said aldehydes to alcohols, where the glycosaminoglycan is heparin, low molecular weight heparin, heparan sulfate or fractions thereof.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: February 15, 2022
    Assignee: Novahealth Biosystems, LLC
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Patent number: 11241449
    Abstract: A galactooligosaccharide composition comprising a mixture of disaccharides, trisaccharides, a tetrasaccharide and a pentasaccharide for use in preventing or treating cognitive dysfunction and/or emotional disturbances in neuropsychiatric illnesses or ageing.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: February 8, 2022
    Assignee: CLASADO RESEARCH SERVICES LIMITED
    Inventor: Georgios Tzortzis
  • Patent number: 11224606
    Abstract: The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: January 18, 2022
    Assignee: Vymedic, LLC
    Inventors: Kenneth E. Phillips, Cynthia A. Winning
  • Patent number: 11224613
    Abstract: The present invention relates to preventing and/or treating urologic diseases and symptoms in humans or domestic animals. The present invention relates also to preventing and/or treating pain in the pelvic area. The invention relates to use of a heteropolysaccharide composition isolated from ligneous plants and comprising hemicelluloses, mainly glucomannans, but also xylans and pectic polysaccharides, as well as fractions, subgroups or mixtures of these, as pharmaceutical preparations, food additives and food products.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: January 18, 2022
    Assignee: MONTINUTRA LTD
    Inventors: Yvonne Konkol, Jenni Bernoulli, Bjarne Holmbom, Heikki Vuorikoski, Andrey Pranovich, Jussi Halleen
  • Patent number: 11224609
    Abstract: Mithramycin side chain carboxylic acid (MTM-SA) derivative are provided, which include a substituted amino acid derivative, a substituted amino acid dipeptide derivative, or an unsubstituted dipeptide derivative. The MTM-SA derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM-SA derivatives have increased selectively toward ETS transcription factor.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: January 18, 2022
    Assignee: University of Kentucky Research Foundation
    Inventors: Jurgen Rohr, Oleg Tsodikov, Markos Leggas, Caixia Hou, Joseph Eckenrode, Prithiba Mitra, Abhisek Mandal
  • Patent number: 11213539
    Abstract: The present invention relates to a combination of ivermectin and brimonidine for use in the treatment and/or the prevention of moderate to severe rosacea, preferably by topical administration of a 1% ivermectin cream and 0.33% brimonidine gel.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: January 4, 2022
    Assignee: GALDERMA HOLDING SA
    Inventors: Philippe Martel, Nabil Kerrouche, Fabien Audibert
  • Patent number: 11207414
    Abstract: The present invention relates to cannabinoid glycoside prodrugs suitable for site- and tissue-specific delivery of cannabinoid molecules. The present invention also relates to methods of forming the cannabinoid glycoside prodrugs through glycosyltransferase mediated glycosylation of cannabinoid molecules.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: December 28, 2021
    Assignee: Graphium Biosciences, Inc.
    Inventors: Brandon J. Zipp, Janee M. Hardman, Robert T. Brooke
  • Patent number: 11208501
    Abstract: The present invention relates to a process for depleting epoxide species in epoxy-crosslinked polysaccharide gel compositions. In addition, the present invention relates to crosslinked polysaccharide gel compositions made by said process and their use in cosmetic and therapeutic applications.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: December 28, 2021
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Ulrich Abel, Andreas Krause
  • Patent number: 11197479
    Abstract: The present invention relates to the use of silthiofam for the treatment of soybean rust and agricultural compositions thereof. The invention further relates to a method of controlling, preventing and/or treating of phytopathogenic fungi causing soybean rust.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: December 14, 2021
    Assignee: Globachem NV
    Inventor: Koen Quaghebeur
  • Patent number: 11197886
    Abstract: The present invention discloses pharmaceutical compositions comprising ester derivatives of hyaluronic acid for use as a topical treatment in disorders of the vaginal mucosa characterised by loss of elasticity and hydration, such as vaginal dryness and/or atrophic vaginitis; said compositions can also be used successfully to lubricate the genital mucosa.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: December 14, 2021
    Assignee: FIDIA FARMACEUTICI S.p.A.
    Inventors: Laura Pilotto, Giovanni Gennari, Anna Maria Zanellato
  • Patent number: 11198765
    Abstract: A method of preparing a hydrogel product comprising crosslinked glycosaminoglycan molecules, said method including: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans include ester crosslinks formed as byproducts during the amide crosslinking; and ii) subjecting the crosslinked glycosaminoglycans to alkaline treatment to hydrolyze ester crosslinks formed as byproducts during the amide crosslinking.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: December 14, 2021
    Assignee: GALDERMA HOLDING SA
    Inventors: Johan Olsson, Hotan Mojarradi
  • Patent number: 11179408
    Abstract: The present invention relates to the use of cyanoglucoside according to formula (I) and formulations thereof in the prevention and/or treatment of diabetes and/or metabolic syndrome; wherein R1, R2 and R3 are independently selected from an optionally substituted mono- or di-saccharide, —O—R4, —O—C(O)—R4 and halogen, such as Cl, F or Br, wherein R4 is selected from H, alkyl, such as methyl, as well as tautomers, geometrical isomers, optically active forms, pharmaceutically acceptable salts and pharmaceutically active derivative thereof.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: November 23, 2021
    Assignees: UNIVERSITÉ DE GENÈVE, UNIVERSIDADE ESTADUAL PAULISTA JÚLIO DE MESQUITA FILHO
    Inventors: Luiz Leonardo Saldanha, Anne Ligia Dokkedal Bosqueiro, Jose Roberto Bosqueiro, Nathalia Aparecida De Paula Camaforte Henriques, Priscilla Maria Ponce Vareda, Wagner Vilegas, Emerson Ferreira Queiroz, Laurence Marcourt, Jean-Luc Wolfender
  • Patent number: 11166968
    Abstract: The present invention relates to compositions, particularly compositions useful in maintaining and supporting healthy microflora in the female urogenital tract which could lead to inhibition of vaginal infections, as well as methods of treating and preventing vaginal infections. Compositions useful in supporting healthy microflora, disclosed herein, generally comprise a therapeutic amount of a first saccharide and a therapeutic amount of a second saccharide or an organic acid. The saccharides may be, for example, a pentose, a disaccharide, a cyclodextrin, a pectic substance or a non-digestible polysaccharide. The organic acid may be, for example, malic acid.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: November 9, 2021
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Jingru Li, Lindsay Adrienne Peed, Cheryce Francina Joyner, Rebecca Ann Vongsa, David William Koenig, Ryan Daniel Bartell, Paige Nicole Hollmaier
  • Patent number: 11166965
    Abstract: The present invention relates to use of a composition for maintenance of bone and/or cartilage health or prevention, alleviation and/or treatment of bone and/or cartilage disorders.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: November 9, 2021
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Marie Noelle Horcajada, Fanny Membrez, Elizabeth Offord Cavin
  • Patent number: 11168106
    Abstract: Nicotinamide ribose has many applications, including as a dietary supplement. This invention convers a process to prepare nicotinamide ribose it in its phosphorylated form. The instant invention is based on the discovery that nicotinamide ribose phosphate emerges in stable form by direct reaction of ribose-1,2-cyclic phosphate. It is based on the further conversion of the phosphorylated nicotinamide ribose product to unphosphorylated nicotinamide ribose upon treatment with an enzymatic phosphatase, most preferably in buffer containing borate. It is based on the further discovery that compositions of nicotinamide ribose with borate slow the decomposition of nicotinamide ribose, and therefore is more useful than compositions of nicotinamide ribose without borate.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: November 9, 2021
    Inventors: Hyo-Joong Kim, Steven A Benner, Ion Mircesti Scorei
  • Patent number: 11160782
    Abstract: A nobiletin composition having high water solubility and a method for easily producing the same are provided. A method for producing a solid dispersion comprising nobiletin, comprising the step of mixing nobiletin or a nobiletin-containing product with a water-soluble hesperidin derivative, and then melting the mixture by heating; and the step of solidifying the melted product by cooling. A nobiletin-containing composition produced by the method.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: November 2, 2021
    Assignee: KAO CORPORATION
    Inventors: Masazumi Iwashita, Masahiro Umehara, Shintaro Onishi, Masaki Yamamoto, Keisuke Yamagami, Takaaki Ishigami
  • Patent number: 11154565
    Abstract: A process is described for preparing a stable emulsion that includes at least one avermectin. Also described, is the emulsion thus obtained, especially for use in the treatment of dermatological disorders such as rosacea.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: October 26, 2021
    Assignee: Galderma Holding SA
    Inventors: Claire Mallard, Richard Dugat, Elodie Roger, Ricardo Diaz
  • Patent number: 11111262
    Abstract: Disclosed herein are new C-mannoside compounds and compositions and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment diseases such as urinary tract infection.
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: September 7, 2021
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Fimbrion Therapeutics, Inc.
    Inventors: Michael Joseph Bishop, Eugene L. Stewart, Katherine Louisa Widdowson, James Walter Janetka, Laurel Kathryn McGrane
  • Patent number: 11110117
    Abstract: Disclosed is a skin preparation composition for external use containing complex hyaluronic acid as an active ingredient, and specifically relates to a skin preparation composition for external use that contains hyaluronic acid, sodium hyaluronate, and hydrolyzed hyaluronic acid as active ingredients, and are excellent in an active oxygen scavenging effect, a wrinkle improvement effect, a moisturizing effect, a skin irritation relief effect, an acne prevention effect, an atopy improvement effect, and an anti-inflammatory effect, an hair damage prevention effect, and a hair loss prevention and hair growth effect.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: September 7, 2021
    Assignees: J2KBIO CO., LTD., COSMECCA KOREA CO., LTD.
    Inventors: Jae Soeb Lee, Jun Tae Bae, Seok Jong Kim, Young Kwon Cha, Hang Eui Cho, Ju Tae Jeong, Kyeong Seok So